142 related articles for article (PubMed ID: 30593830)
1. Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies.
Guillaume T; Dehame V; Chevallier P; Peterlin P; Garnier A; Grégoire M; Pichinuk E; Rubinstein DB; Wreschner DH
Exp Hematol; 2019 Feb; 70():97-108. PubMed ID: 30593830
[TBL] [Abstract][Full Text] [Related]
2. In vivo anti-MUC1
Pichinuk E; Chalik M; Benhar I; Ginat-Koton R; Ziv R; Smorodinsky NI; Haran G; Garbar C; Bensussan A; Meeker A; Guillaume T; Rubinstein DB; Wreschner DH
Cancer Immunol Immunother; 2020 Jul; 69(7):1337-1352. PubMed ID: 32219500
[TBL] [Abstract][Full Text] [Related]
3. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D
Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470
[TBL] [Abstract][Full Text] [Related]
4. The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/beta junction mediates cell killing.
Rubinstein DB; Karmely M; Pichinuk E; Ziv R; Benhar I; Feng N; Smorodinsky NI; Wreschner DH
Int J Cancer; 2009 Jan; 124(1):46-54. PubMed ID: 18821582
[TBL] [Abstract][Full Text] [Related]
5. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells.
Pichinuk E; Benhar I; Jacobi O; Chalik M; Weiss L; Ziv R; Sympson C; Karwa A; Smorodinsky NI; Rubinstein DB; Wreschner DH
Cancer Res; 2012 Jul; 72(13):3324-36. PubMed ID: 22507854
[TBL] [Abstract][Full Text] [Related]
6. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
7. Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
Lo TH; Abadir E; Gasiorowski RE; Kabani K; Ramesh M; Orellana D; Fromm PD; Kupresanin F; Newman E; Cunningham I; Hart DNJ; Silveira PA; Clark GJ
PLoS One; 2019; 14(5):e0216368. PubMed ID: 31075107
[TBL] [Abstract][Full Text] [Related]
8. Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.
Sun Q; So CC; Yip SF; Wan TS; Ma SK; Chan LC
Leuk Res; 2008 Sep; 32(9):1374-81. PubMed ID: 18372040
[TBL] [Abstract][Full Text] [Related]
9. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.
Hartman M; Baruch A; Ron I; Aderet Y; Yoeli M; Sagi-Assif O; Greenstein S; Stadler Y; Weiss M; Harness E; Yaakubovits M; Keydar I; Smorodinsky NI; Wreschner DH
Int J Cancer; 1999 Jul; 82(2):256-67. PubMed ID: 10389761
[TBL] [Abstract][Full Text] [Related]
10. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
McGraw KJ; Rosenblum MG; Cheung L; Scheinberg DA
Cancer Immunol Immunother; 1994 Dec; 39(6):367-74. PubMed ID: 8001024
[TBL] [Abstract][Full Text] [Related]
11. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
Rubinstein DB; Karmely M; Ziv R; Benhar I; Leitner O; Baron S; Katz BZ; Wreschner DH
Cancer Res; 2006 Dec; 66(23):11247-53. PubMed ID: 17145869
[TBL] [Abstract][Full Text] [Related]
12. Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy.
Kovjazin R; Horn G; Smorodinsky NI; Shapira MY; Carmon L
PLoS One; 2014; 9(1):e85400. PubMed ID: 24416403
[TBL] [Abstract][Full Text] [Related]
13. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
14. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
15. CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.
Abadir E; Gasiorowski RE; Lai K; Kupresanin F; Romano A; Silveira PA; Lo TH; Fromm PD; Kennerson ML; Iland HJ; Ho PJ; Hogarth PM; Bradstock K; Hart DNJ; Clark GJ
Mol Oncol; 2019 Oct; 13(10):2107-2120. PubMed ID: 31338922
[TBL] [Abstract][Full Text] [Related]
16. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Nguyen DH; Ball ED; Varki A
Exp Hematol; 2006 Jun; 34(6):728-35. PubMed ID: 16728277
[TBL] [Abstract][Full Text] [Related]
17. Novel Antibodies Targeting MUC1-C Showed Anti-Metastasis and Growth-Inhibitory Effects on Human Breast Cancer Cells.
Kim MJ; Choi JR; Tae N; Wi TM; Kim KM; Kim DH; Lee ES
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380650
[TBL] [Abstract][Full Text] [Related]
18. The MUC1 SEA module is a self-cleaving domain.
Levitin F; Stern O; Weiss M; Gil-Henn C; Ziv R; Prokocimer Z; Smorodinsky NI; Rubinstein DB; Wreschner DH
J Biol Chem; 2005 Sep; 280(39):33374-86. PubMed ID: 15987679
[TBL] [Abstract][Full Text] [Related]
19. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
[TBL] [Abstract][Full Text] [Related]
20. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
